The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
39
No.
45
December 17, 2013
- Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles With SEC Over Shorting Dendreon Stock
- An Earmark In The Making? NCI Urged to Boost Gastric Cancer Funding
- In Brief: LENORA JOHNSON Was Named Director Of Health Education, Communications, And Science Policy at the National Heart Lung and Blood Institute
- FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.
CCL
Vol.
36
No.
12
December 27, 2013
- Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival
- Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis
- Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL
- Biomarker May Predict Prostate Cancer Metastases
- Individualized Cancer Vaccines Show 90% Survival at 6 Months
- Dendritic Cell Vaccine Increases PFS in Phase II Clinical Trial
- Two Phase II Studies of Ibrutinib Deliver High Response Rates
- NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent
- Study: BRCA2-Negative Women Could Still Have High Risk
- Velcade Addition Can Improve Graft-Versus-Host Outcomes
- NCI CTEP Approved Trials For the Month of December
- FDA Expands Nexavar Indication To Include Thyroid Cancer
